Crimson Publishers Publish With Us Reprints e-Books Video articles


Significances of Bioengineering & Biosciences

Novel Potential Biomarkers in Cardiovascular Diseases

  • Open or CloseBogdan-Ioan Coculescu1,2*, Gheorghe Manole3, Valeriu Gabi Dinca2 and Elena Claudia Coculescu4

    1Cantacuzino National Medico-Military Institute for Research and Development, Romania

    2Faculty of Medicine, Titu Maiorescu University, Romania

    3Faculty of General Nursing, Bioterra University, Romania

    4Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, Romania

    *Corresponding author: Bogdan-Ioan Coculescu, Cantacuzino National Medico- Military Institute for Research and Development, 103 Splaiul Independenței, 050096, Bucharest, Romania

Submission: August 23, 2021;Published: September 20, 2021

DOI: 10.31031/SBB.2021.05.000611

ISSN 2637-8078
Volume 5 Issue 3


One of the critical medical topics researched is identifying the most diverse diseases of new molecular biomarkers that would establish a positive diagnosis and respond to an indeed shown treatment (risk biomarkers). Prolonging the lifespan of individuals and increasing the frequency of heart failure from 1-2% in the adult population, regardless of age, to 10-12% in people over 70 explains the worldwide interest in identifying biomarkers and in this condition, regardless of etiology, which offers the possibility of complex assessment of the situation, including the prognosis. In the studies published so far, we aimed to demonstrate the involvement of enzymes as biomarkers of diastolic dysfunction generating heart failure (i.e., we studied the possibility of osteopontin as a biomarker of heart damage and injury, because it is involved in the generation of myocardial inflammation, a process present in the deficient contractile myocardium). For medical practice, in the variant in which the research efforts of some of these will impose them as biomarkers, they become a means/method of diagnosis of the studied heart disease, which allows significant reduction of decision times and prompt/early initiation of therapy. The effects are beneficial for both the patient, the family and society, as they are real forms of secondary prevention and reduction of hospitalization costs.

Keywords: Cardiovascular diseases; Atherosclerosis; Risk biomarkers

Abbreviations: TNF: Tumor Necrosis Factor; IL-1: Interleukin-1; G-CSF: Granulocyte Colony- Stimulating Factor; M-CSF: Monocyte Colony-Stimulating Factor

Get access to the full text of this article